Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Swiss National Bank

Swiss National Bank lessened its position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 2.6% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 1,193,200 shares of the biopharmaceutical company's stock after selling 32,300 shares during the period. Swiss National Bank owned approximately 0.20% of Royalty Pharma worth $33,517,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. Xponance Inc. lifted its position in Royalty Pharma by 38.8% in the 3rd quarter. Xponance Inc. now owns 18,218 shares of the biopharmaceutical company's stock valued at $494,000 after acquiring an additional 5,090 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Royalty Pharma by 75.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 209,576 shares of the biopharmaceutical company's stock valued at $5,612,000 after buying an additional 90,282 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Royalty Pharma by 103.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 79,990 shares of the biopharmaceutical company's stock worth $2,171,000 after buying an additional 40,582 shares in the last quarter. Inspire Investing LLC purchased a new stake in Royalty Pharma in the 3rd quarter valued at $364,000. Finally, TD Asset Management Inc lifted its stake in Royalty Pharma by 49.4% during the 3rd quarter. TD Asset Management Inc now owns 290,483 shares of the biopharmaceutical company's stock valued at $7,884,000 after acquiring an additional 96,026 shares in the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.

Royalty Pharma Stock Performance

Shares of RPRX stock traded down $0.29 on Wednesday, hitting $27.99. 3,493,972 shares of the stock were exchanged, compared to its average volume of 2,710,349. Royalty Pharma plc has a one year low of $25.92 and a one year high of $35.52. The firm's 50 day moving average is $29.25 and its two-hundred day moving average is $28.59. The firm has a market capitalization of $16.72 billion, a PE ratio of 14.81 and a beta of 0.47. The company has a current ratio of 7.90, a quick ratio of 7.90 and a debt-to-equity ratio of 0.61.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its earnings results on Thursday, February 15th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.12. The firm had revenue of $736.00 million during the quarter, compared to the consensus estimate of $702.90 million. Royalty Pharma had a net margin of 48.22% and a return on equity of 26.93%. Sell-side analysts expect that Royalty Pharma plc will post 3.95 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 17th will be issued a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.00%. The ex-dividend date is Thursday, May 16th. Royalty Pharma's payout ratio is currently 44.44%.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on RPRX. JPMorgan Chase & Co. lowered their target price on shares of Royalty Pharma from $45.00 to $42.00 and set an "overweight" rating for the company in a report on Tuesday, February 20th. The Goldman Sachs Group reduced their target price on Royalty Pharma from $56.00 to $50.00 and set a "buy" rating for the company in a report on Tuesday, February 20th. StockNews.com upgraded Royalty Pharma from a "hold" rating to a "buy" rating in a research note on Thursday, April 11th. Finally, Bank of America lowered their target price on Royalty Pharma from $40.00 to $38.00 and set a "buy" rating on the stock in a research note on Friday, April 12th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $46.75.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.